Supply of Vosoritide (DOE)

This tender concerns the supply of Vosoritide, identified by the designation DOE. Vosoritide is a pharmaceutical product, specifically a C-type natriuretic peptide (CNP) analog, used in the treatment of achondroplasia, a genetic disorder affecting bone growth. The tender is seeking a qualified supplier or manufacturer capable of providing this specialized medication. Key requirements likely include adherence to stringent pharmaceutical quality standards, regulatory compliance for drug supply, and potentially specific packaging and delivery protocols to maintain product integrity. The scope of the contract will involve the procurement and delivery of Vosoritide, ensuring a consistent and reliable supply chain for healthcare providers or relevant institutions. Further details regarding the quantities required, delivery timelines, and specific technical specifications for the product will be elaborated in the full tender documentation. Interested parties are advised to review the complete tender package to understand all eligibility criteria, submission procedures, and evaluation methodologies. This procurement is crucial for ensuring patient access to an important therapeutic agent for a rare genetic condition.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Spain, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.